Concepts (123)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| T-Lymphocytes, Regulatory | 8 | 2011 | 717 | 0.600 |
Why?
|
| STAT3 Transcription Factor | 8 | 2012 | 1140 | 0.570 |
Why?
|
| Glioblastoma | 5 | 2012 | 1844 | 0.560 |
Why?
|
| Immune Tolerance | 4 | 2010 | 408 | 0.470 |
Why?
|
| Brain Neoplasms | 13 | 2012 | 4994 | 0.460 |
Why?
|
| Neoplastic Stem Cells | 4 | 2011 | 1472 | 0.460 |
Why?
|
| Tyrphostins | 4 | 2011 | 108 | 0.330 |
Why?
|
| T-Lymphocytes | 3 | 2010 | 3955 | 0.300 |
Why?
|
| Topotecan | 1 | 2008 | 241 | 0.300 |
Why?
|
| Th2 Cells | 1 | 2007 | 262 | 0.270 |
Why?
|
| Th1 Cells | 1 | 2007 | 259 | 0.270 |
Why?
|
| Forkhead Transcription Factors | 2 | 2009 | 770 | 0.230 |
Why?
|
| Glioma | 6 | 2012 | 2001 | 0.210 |
Why?
|
| Pyridines | 4 | 2011 | 1292 | 0.200 |
Why?
|
| Signal Transduction | 7 | 2015 | 12143 | 0.170 |
Why?
|
| Immunotherapy | 3 | 2010 | 3482 | 0.160 |
Why?
|
| Melanoma, Experimental | 2 | 2011 | 377 | 0.150 |
Why?
|
| Lymphocyte Activation | 2 | 2010 | 1698 | 0.120 |
Why?
|
| Cell Line, Tumor | 7 | 2012 | 14857 | 0.120 |
Why?
|
| Mice, Nude | 3 | 2012 | 4343 | 0.120 |
Why?
|
| Amine Oxidase (Copper-Containing) | 1 | 2013 | 3 | 0.120 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2015 | 305 | 0.110 |
Why?
|
| Oncolytic Viruses | 1 | 2015 | 186 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2012 | 80 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 7 | 2012 | 7188 | 0.100 |
Why?
|
| Tumor Escape | 2 | 2010 | 253 | 0.100 |
Why?
|
| Cell Adhesion Molecules | 1 | 2013 | 587 | 0.090 |
Why?
|
| Cause of Death | 1 | 2013 | 796 | 0.090 |
Why?
|
| Mice | 9 | 2012 | 35347 | 0.090 |
Why?
|
| Mice, Inbred BALB C | 3 | 2012 | 2403 | 0.090 |
Why?
|
| Adenoviridae | 1 | 2015 | 1455 | 0.080 |
Why?
|
| Cell Proliferation | 3 | 2012 | 7306 | 0.080 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2008 | 83 | 0.080 |
Why?
|
| Autophagy | 1 | 2015 | 931 | 0.080 |
Why?
|
| Chemokines | 1 | 2010 | 319 | 0.080 |
Why?
|
| Cytomegalovirus | 1 | 2011 | 483 | 0.080 |
Why?
|
| Cell Separation | 1 | 2010 | 599 | 0.080 |
Why?
|
| Fas Ligand Protein | 1 | 2008 | 153 | 0.080 |
Why?
|
| Animals | 11 | 2012 | 61014 | 0.080 |
Why?
|
| Cell Differentiation | 2 | 2010 | 4170 | 0.070 |
Why?
|
| Transplantation, Heterologous | 1 | 2010 | 1091 | 0.070 |
Why?
|
| CD3 Complex | 1 | 2008 | 316 | 0.070 |
Why?
|
| Apoptosis | 3 | 2012 | 7757 | 0.070 |
Why?
|
| fas Receptor | 1 | 2008 | 193 | 0.070 |
Why?
|
| Monocytes | 1 | 2011 | 786 | 0.070 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2008 | 688 | 0.070 |
Why?
|
| Neovascularization, Pathologic | 1 | 2012 | 1577 | 0.060 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2012 | 1261 | 0.060 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2012 | 3931 | 0.060 |
Why?
|
| Phosphoproteins | 1 | 2010 | 1179 | 0.060 |
Why?
|
| Interferon-gamma | 1 | 2008 | 1163 | 0.060 |
Why?
|
| Cyclophosphamide | 1 | 2011 | 3145 | 0.060 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 1431 | 0.060 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2008 | 1007 | 0.060 |
Why?
|
| Up-Regulation | 1 | 2008 | 2480 | 0.050 |
Why?
|
| Cytokines | 2 | 2008 | 2871 | 0.050 |
Why?
|
| Flow Cytometry | 1 | 2008 | 3074 | 0.050 |
Why?
|
| Tumor Microenvironment | 1 | 2011 | 2980 | 0.050 |
Why?
|
| Humans | 14 | 2015 | 270789 | 0.040 |
Why?
|
| Colorectal Neoplasms | 1 | 2013 | 3698 | 0.040 |
Why?
|
| Disease Models, Animal | 4 | 2012 | 7431 | 0.040 |
Why?
|
| Mice, Transgenic | 2 | 2012 | 4246 | 0.030 |
Why?
|
| Nestin | 1 | 2012 | 45 | 0.030 |
Why?
|
| Intermediate Filament Proteins | 1 | 2012 | 83 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2012 | 16277 | 0.030 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2012 | 169 | 0.030 |
Why?
|
| Oncolytic Virotherapy | 1 | 2015 | 257 | 0.030 |
Why?
|
| Administration, Metronomic | 1 | 2011 | 15 | 0.030 |
Why?
|
| Chickens | 1 | 2012 | 527 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2012 | 335 | 0.020 |
Why?
|
| Melanoma | 1 | 2008 | 5449 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2012 | 572 | 0.020 |
Why?
|
| HL-60 Cells | 1 | 2011 | 306 | 0.020 |
Why?
|
| Phosphorylation | 2 | 2008 | 4885 | 0.020 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2011 | 188 | 0.020 |
Why?
|
| Genes, bcl-2 | 1 | 2010 | 168 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2012 | 1079 | 0.020 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 1 | 2008 | 102 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2012 | 947 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 1233 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2011 | 491 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2011 | 705 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2012 | 1350 | 0.020 |
Why?
|
| Quinazolines | 1 | 2012 | 934 | 0.020 |
Why?
|
| Prognosis | 3 | 2010 | 22259 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2012 | 1810 | 0.020 |
Why?
|
| Central Nervous System | 1 | 2010 | 449 | 0.020 |
Why?
|
| Immunologic Factors | 1 | 2011 | 667 | 0.020 |
Why?
|
| Cytomegalovirus Infections | 1 | 2011 | 465 | 0.020 |
Why?
|
| Survival Rate | 2 | 2012 | 12449 | 0.020 |
Why?
|
| Cell Line | 1 | 2015 | 5132 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2012 | 2221 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2012 | 3596 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2009 | 596 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 3666 | 0.020 |
Why?
|
| Macrophages | 1 | 2012 | 1372 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2008 | 14507 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2012 | 1692 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2012 | 1508 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 5023 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2012 | 5670 | 0.010 |
Why?
|
| Pyrazoles | 1 | 2012 | 1523 | 0.010 |
Why?
|
| Cell Movement | 1 | 2011 | 2501 | 0.010 |
Why?
|
| Female | 5 | 2013 | 147324 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2012 | 6225 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2013 | 9323 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2012 | 7705 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2012 | 3363 | 0.010 |
Why?
|
| Disease Progression | 1 | 2012 | 6892 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2012 | 3611 | 0.010 |
Why?
|
| Phenotype | 1 | 2011 | 6400 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2012 | 9067 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2009 | 9484 | 0.010 |
Why?
|
| Aged | 2 | 2013 | 72942 | 0.010 |
Why?
|
| Middle Aged | 2 | 2013 | 89585 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2008 | 16760 | 0.010 |
Why?
|
| Male | 2 | 2013 | 127666 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2010 | 34228 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2008 | 30827 | 0.010 |
Why?
|
| Adolescent | 1 | 2008 | 32336 | 0.000 |
Why?
|
| Child | 1 | 2008 | 30138 | 0.000 |
Why?
|
| Retrospective Studies | 1 | 2009 | 39484 | 0.000 |
Why?
|
| Adult | 1 | 2008 | 80741 | 0.000 |
Why?
|